drugset
Drugs / Copper Cu-64-DOTA-alendronate
last change May 2024 re-read 3 minutes ago

Copper Cu-64-DOTA-alendronate

Diagnostic / imaging agent

Investigated by
City of Hope Medical Center · National Cancer Institute (NCI)

Trials 1

today NCT03542695 · Ph 0
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT03542695 Nov 2021 → May 2024 breast carcinoma, calcinosis City of Hope Medical Center Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Copper Cu-64-DOTA-alendronate ClinicalTrials.gov intervention name — accepted as the source's own label NCT03542695 ↗
Modality Diagnostic / imaging agent “Diagnostic procedures, such 64Cu-DOTA-alendronate PET, may detect calcification” NCT03542695 ↗
Route Intravenous “Participants receive 64Cu-DOTA-alendronate intravenously (IV)” NCT03542695 ↗